158 related articles for article (PubMed ID: 21173237)
21. Highly aggressive behavior of malignant rhabdoid tumor: a special reference to SMARCB1/INI1 gene alterations using molecular genetic analysis including quantitative real-time PCR.
Kohashi K; Oda Y; Yamamoto H; Tamiya S; Izumi T; Ohta S; Taguchi T; Suita S; Tsuneyoshi M
J Cancer Res Clin Oncol; 2007 Nov; 133(11):817-24. PubMed ID: 17486366
[TBL] [Abstract][Full Text] [Related]
22. Potent inhibition of rhabdoid tumor cells by combination of flavopiridol and 4OH-tamoxifen.
Cimica V; Smith ME; Zhang Z; Mathur D; Mani S; Kalpana GV
BMC Cancer; 2010 Nov; 10():634. PubMed ID: 21092078
[TBL] [Abstract][Full Text] [Related]
23. SMARCB1/INI1 inactivation in renal medullary carcinoma.
Calderaro J; Moroch J; Pierron G; Pedeutour F; Grison C; Maillé P; Soyeux P; de la Taille A; Couturier J; Vieillefond A; Rousselet MC; Delattre O; Allory Y
Histopathology; 2012 Sep; 61(3):428-35. PubMed ID: 22686875
[TBL] [Abstract][Full Text] [Related]
24. Integrated genomics has identified a new AT/RT-like yet INI1-positive brain tumor subtype among primary pediatric embryonal tumors.
Ho DM; Shih CC; Liang ML; Tsai CY; Hsieh TH; Tsai CH; Lin SC; Chang TY; Chao ME; Wang HW; Wong TT
BMC Med Genomics; 2015 Jun; 8():32. PubMed ID: 26109171
[TBL] [Abstract][Full Text] [Related]
25. hSNF5/INI1 inactivation is mainly associated with homozygous deletions and mitotic recombinations in rhabdoid tumors.
Rousseau-Merck MF; Versteege I; Legrand I; Couturier J; Mairal A; Delattre O; Aurias A
Cancer Res; 1999 Jul; 59(13):3152-6. PubMed ID: 10397258
[TBL] [Abstract][Full Text] [Related]
26. Integrase interactor 1 regulates proliferation, apoptosis and invasion in gastric cancer cells.
Wang XC; Li Y; Fan LQ; Tan BB; Li Z; Liu Y; Zhang ZD
Chin Med J (Engl); 2012 Feb; 125(3):527-32. PubMed ID: 22490415
[TBL] [Abstract][Full Text] [Related]
27. SMARCB1/INI1 protein expression in round cell soft tissue sarcomas associated with chromosomal translocations involving EWS: a special reference to SMARCB1/INI1 negative variant extraskeletal myxoid chondrosarcoma.
Kohashi K; Oda Y; Yamamoto H; Tamiya S; Oshiro Y; Izumi T; Taguchi T; Tsuneyoshi M
Am J Surg Pathol; 2008 Aug; 32(8):1168-74. PubMed ID: 18580682
[TBL] [Abstract][Full Text] [Related]
28. P16INK4a is required for hSNF5 chromatin remodeler-induced cellular senescence in malignant rhabdoid tumor cells.
Oruetxebarria I; Venturini F; Kekarainen T; Houweling A; Zuijderduijn LM; Mohd-Sarip A; Vries RG; Hoeben RC; Verrijzer CP
J Biol Chem; 2004 Jan; 279(5):3807-16. PubMed ID: 14604992
[TBL] [Abstract][Full Text] [Related]
29. Alterations of the hSNF5/INI1 gene in central nervous system atypical teratoid/rhabdoid tumors and renal and extrarenal rhabdoid tumors.
Biegel JA; Tan L; Zhang F; Wainwright L; Russo P; Rorke LB
Clin Cancer Res; 2002 Nov; 8(11):3461-7. PubMed ID: 12429635
[TBL] [Abstract][Full Text] [Related]
30. SMARCB1 deletion by a complex three-way chromosomal translocation in an extrarenal malignant rhabdoid tumor.
Bahrami A; Lee S; Caradine KD; Raimondi SC; Folpe AL
Cancer Genet; 2014 Sep; 207(9):437-40. PubMed ID: 25312828
[TBL] [Abstract][Full Text] [Related]
31. Oncogenic roles of SMARCB1/INI1 and its deficient tumors.
Kohashi K; Oda Y
Cancer Sci; 2017 Apr; 108(4):547-552. PubMed ID: 28109176
[TBL] [Abstract][Full Text] [Related]
32. The requirement for SNF5/INI1 in adipocyte differentiation highlights new features of malignant rhabdoid tumors.
Caramel J; Medjkane S; Quignon F; Delattre O
Oncogene; 2008 Mar; 27(14):2035-44. PubMed ID: 17922027
[TBL] [Abstract][Full Text] [Related]
33. Rhabdoid tumor: gene expression clues to pathogenesis and potential therapeutic targets.
Gadd S; Sredni ST; Huang CC; Perlman EJ;
Lab Invest; 2010 May; 90(5):724-38. PubMed ID: 20212451
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis of novel peptidomimetic derivatives of 4-HPR for rhabdoid tumors.
Das BC; Smith ME; Kalpana GV
Bioorg Med Chem Lett; 2008 Jul; 18(14):4177-80. PubMed ID: 18556204
[TBL] [Abstract][Full Text] [Related]
35. SWI/SNF mediates polycomb eviction and epigenetic reprogramming of the INK4b-ARF-INK4a locus.
Kia SK; Gorski MM; Giannakopoulos S; Verrijzer CP
Mol Cell Biol; 2008 May; 28(10):3457-64. PubMed ID: 18332116
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical analysis of hSNF5/INI1 in pediatric CNS neoplasms.
Judkins AR; Mauger J; Ht A; Rorke LB; Biegel JA
Am J Surg Pathol; 2004 May; 28(5):644-50. PubMed ID: 15105654
[TBL] [Abstract][Full Text] [Related]
37. Growth inhibition and induction of apoptosis by flavopiridol in rat lung adenocarcinoma, osteosarcoma and malignant fibrous histiocytoma cell lines.
Honoki K; Yoshitani K; Tsujiuchi T; Mori T; Tsutsumi M; Morishita T; Takakura Y; Mii Y
Oncol Rep; 2004 May; 11(5):1025-30. PubMed ID: 15069542
[TBL] [Abstract][Full Text] [Related]
38. Loss of IGFBP7 expression and persistent AKT activation contribute to SMARCB1/Snf5-mediated tumorigenesis.
Darr J; Klochendler A; Isaac S; Eden A
Oncogene; 2014 Jun; 33(23):3024-32. PubMed ID: 23851500
[TBL] [Abstract][Full Text] [Related]
39. Cyclin D1 amplification is independent of p16 inactivation in head and neck squamous cell carcinoma.
Okami K; Reed AL; Cairns P; Koch WM; Westra WH; Wehage S; Jen J; Sidransky D
Oncogene; 1999 Jun; 18(23):3541-5. PubMed ID: 10376532
[TBL] [Abstract][Full Text] [Related]
40. Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways.
Wu K; Wang C; D'Amico M; Lee RJ; Albanese C; Pestell RG; Mani S
Mol Cancer Ther; 2002 Jul; 1(9):695-706. PubMed ID: 12479366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
